NDUFAF2 and bladder transitional cell carcinoma: In addition, a lower expression of NDUFAF2 was observed in breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical (CESC), bladder urothelial carcinoma (BLCA), esophageal carcinoma (ESCA), acute myeloid leukemia (LAML), kidney chromophobe carcinoma (KICH), ovarian serous cystadenocarcinoma (OV), and testicular germ cell tumors (TGCT) (Figure 1(a)).